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Poster Session-I 53presentation, treatment and risk-factors. AVN was defined as the
presence of joint symptoms with confirmatory radiological findings
on X-ray, CT or MRI at any time after HCT. Among 3527 HCT
recipients from 1990–2007, 73 (2.1%) cases of post-HCT AVN
were identified; of these, 8 (0.7%) occurred after autologous and
65 (2.7%) after allogeneic HCT (sibling 33, unrelated 19, umbilical
cord blood 13). Median age at HCT for cases was 29 (range, 4–60)
years and included 23% pediatric recipients (\18 years). Median fol-
lowup was 7 (range, 1–16) years. Myeloablative conditioning was
used in 74% and 77% received total body irradiation (TBI). Acute
and chronic graft-versus-host disease (GVHD) occurred in 69%
and 65%, respectively. Use of prednisone (or equivalent) was very
prevalent; 8%had receivedno prednisone, 23%had received a cumu-
lative dose of #0.5 mg/kg/day, and 69% had received .0.5 mg/kg/
day prior to diagnosis of AVN. AVN affected 155 joints in these 73
patients (median number of joints involved 2 [range, 1–6]) and was
diagnosed at a median of 18 months (interquartile range 11–33
months) post-HCT. Proximal femur (54%) and distal femur (36%)
were the most common sites. Association Research Circulation
Osseous stage, which classifies progressively worsening radiological
abnormalities and amount of bone involvement from stage 0–4,
could be assigned for 52 cases; of these, stage 3 or 4 (that requires sur-
gical intervention) was present in 60%. Thirty-five (48%) received
surgical treatment for AVN, among which joint replacement was
performed in 31 patients. Risk factor analysis was performed using
a randomly selected cohort of 148 HCT recipients frequency
matched by age, gender and year of HCT and with no joint symp-
toms. Risk of AVN was higher in allogeneic HCT recipients (odds
ratio (OR) 2.7 (95%CI, 1.2–6.2), P5 0.01) andwith exposure to cor-
ticosteroids (OR 15.9 (6.5–39.1), p\ 0.01); diagnosis, conditioning
intensity and use of TBI did not increase its risk. In conclusion, AVN
is a relatively rare complication of HCT, typically occurs within the
first 3 years after HCT, presents with advanced stages and frequently
requires surgical management. Allogeneic HCT recipients, espe-
cially those exposed to corticosteroids, are at highest risk and may
benefit from screening for early detection and treatment to avoid
joint replacement surgery.139
DIAGNOSIS OF MENTAL HEALTH DISORDER DOES NOT EFFECT
OUTCOME IN ALLOGENEIC BONE MARROW TRANSPLANT
Khan, G.1, Sproat, L.2, Bolwell, B.2, Rybicki, L.2, Kalaycio, M.2,
Dean, R.2, Sobecks, R.2, Pohlman, B.2, Andresen, S.2, Sweetenham, J.2,
Copelan, E.2 1Cleveland Clinic Medicine Institute, Cleveland, OH;
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Background: Psychiatric disturbance before allogeneic stem cell
transplant (allo-SCT) has been associated with worse survival and
quality of life and is used in predictive indices for transplant out-
come.
Methods:We report a retrospective study that analyzed 142 pa-
tients who underwent fully ablative allo-SCT between January
2005 and June 2008. Patients with mental health disorder
(MHDx) were identified from pre-transplant psychosocial assess-
ment and physician evaluation before transplant. Patients were as-
signed MHDx if they were taking psychotropic medication or
specific MHDx was documented. Wilcoxon rank sum and Chi-
square tests were used to compare patients withMHDx to patients
without MHDx. Outcomes between these groups were estimated
using the Kaplan-Meier method via the log rank test.
Results: We identified 41 patients with MHDx and 101 patients
without. The Wilcoxon rank sum test analysis showed that patients
with MHDx had a significantly longer period from diagnosis to
transplant (P 5 0.001). Patients with MHDx had an increased inci-
dence of acute graft versus host disease (AGVHD) (P 5 0.003),
but not chronic graft versus host disease (CGVHD) (P 5 0.30).
Kaplan-Meier analysis showed no significant statistical difference
in Relapse Mortality (RM) (0.31), Non-Relapse Mortality (NRM)
(P 5 0.41) or Overall Survival (OS) (P 5 0.99). (See table below.)
One and two-year survival for patients with MHDx (56.2% and
47.2% respectively) and without MHDx (57.2% and 44.2% respec-
tively) were not statistically significant.
Conclusion: Identifying comorbidities that have an impact on
post-transplant survival is crucial to improving transplant outcome.
While this study shows no statistical association betweenMHDx andOS, RM or NRM it demonstrates a significant association of MHDx
on time period from diagnosis to transplant and incidence of
AGVHD. Identifying patients with MHDx early in pre-transplant
staging and initiating appropriate treatment might reduce time to
transplant and AGVHD. Providing targeted psychosocial services
could lead to an overall improved quality of life. This study did
not indicate that MHdx leads to worse outcome. Further investiga-
tion into pre-transplant MHdx and its role in pre-transplant care
as well as in transplant is warranted.
No MHD MHDx P-valueMonths from Diagnosis to
Transplant (mean 1SD)9.9 1 14.6 19.1 1 23.0 0.001AGVHD 59 / 101 (58.4%) 33 / 41 (80.5%) 0.003
CGVHD 33 / 101 (32.7%) 9 / 41 (22.0%) 0.30
Non-Relapse Mortality 28 / 101 (27.7%) 14 / 41 (34.1%) 0.41
Relapse Mortality 22 / 101 (21.8%) 5 / 41 (12.2%) 0.31
Overall Survival 51 / 101 (51.5%) 22 / 41 (53.7%) 0.99140
ALLELIC VARIATION IN TP53 AND MDM2 DNA REPAIR GENES CONSTI-
TUTE GENETIC RISK FACTORS FOR LONG-TERM SURVIVAL IN ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Dupont, B.1, Malkki, M.2, Gooley, T.2, Wang, H.2, Zhao, L.P.2,
Bojesen, S.E.3, Petersdorf, E.W.2, Hansen, J.A.2 1Memorial Sloan Ketter-
ing Cancer Center, New York, NY; 2Fred Hutchinson Cancer Reserch
Center, Seattle, WA; 3Herlev University Hospital, Herlev, Denmark
The p53 tumor suppressor pathway plays a major role in tumor
development and cell survival. Germline single nucleotide poly-
morphisms (SNP)s in codon 72 of TP53 (Arg72Pro; rs1042522)
and in the promoter region of the ubiquitin ligase MDM2 (-309;
rs2279744) influence apoptotic activity in response to cellular
stress. In vitro studies have demonstrated that cells homozygous
for Arg72 in p53 have significantly increased apoptotic activity in
response to cellular stress, while cells homozygous for Pro72
have increase in cell cycle arrest and DNA repair. We recently in-
vestigated the impact of these two SNPs on survival after transplan-
tation from HLA 10/10 matched unrelated donors. In brief,
analysis of samples and clinical outcome data contributed by the
National Marrow Donor Program Research Sample Repository
and by the Center for International Blood and Marrow Transplant
Research, respectively, demonstrated that patients with two p53
72Pro alleles and at least one copy of the MDM2-309 G allele
had an increase in mortality risk compared to patients with 2 p53
72Pro alleles and zero G alleles at -309 (HR 5 1.41). We now re-
port the results of a second independent cohort of donor-recipient
pairs tested for the same p53 and MDM2 SNPs. All patients were
treated at the Fred Hutchinson Cancer Research Center and repre-
sented 731 related and 669 unrelated pairs including HLAmatched
and mismatched cases. We find that patients with two p53 72Pro
alleles and at least one copy of theMDM2-309 G allele had a signif-
icant increase in mortality risk compared to patients with 2 p53
72Pro alleles and zero G alleles at -309 (HR 5 1.35). These results
are consistent with our hypothesis that the combination of recipient
genotypes for p53 Arg72/Pro and SNP -309 MDM2 affects post
transplantation survival. Detailed analysis of other clinical outcome
data are currently in progress.141
TASTE DISORDERS AND ORAL CLINIC EVALUATION IN PATIENTS SUBMIT-
TED TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
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tology and Blood Transfusion Center, Campinas, Sao Paulo, Brazil; Hema-
tology and Blood Transfusion Center, Campinas, Sao Paulo, Brazil;
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Graft versus host disease can affect the oral cavity leading to mu-
cosal salivary gland damages and causing change in taste perception.
54 Poster Session-ITaste disorders are rarely discussed in the literature, it’s a significant
and prevalent problem reported by HSCT patients. The etiology of
taste disorders is multifactorial, however, the understanding of this
complain in this special group of patient should be better investi-
gated. The aim of this study was to evaluate prospectively, taste per-
ception, salivary flow rate and oral conditions in three different
groups of 61 adults patients submitted to allogeneic myeloablative
and non-myeloablative HSCT considering post-transplant timing.
Patients were classified into Group I(n5 20), up to 150 days, Group
II(n 5 20), between 151–1094 days, and Group III(n 5 21), above
1094 days. Taste acuity was measured by the taste thresholds for
the four basic tastes using 5ml of 4 solutions, in 3 concentration-
s(mol/L): NaCl(0.01;0.50;1.00), sucrose(0.01;0.50;1.00), citric
acid(0.32;0.0158;0.032), caffeine(1.988  10-5;0.644  10-2;1.277
 10–2). Patients considered flavors and their intensity as high,
medium and low. Unstimulated saliva was collected into separate
pre-weight plastic test glass and salivary flow rates were determinate
in ml/m. Oral cavity was examined in order to verify the presence of
GVHD, the presence of pain and oral infections. From those 61
patients, 31 presented cGVHD(Group I 5 3; Group II 5 14 and
Group III 5 14). In general, the sour and bitter perception was
not different between the 3 groups. The intensity of the sweet solu-
tion in the high and low concentrations were a challenging to be de-
termined for those patients(p5 0.04 and p5 0.05 respectively). For
the medium salty concentration and high sucrose concentration the
tastes were difficult to be determined only by the Group I(p 5 0.08
and p5 0.07 respectively). The saliva flow rate was diminished in 10/
61 patients in all periods(1.36 (0.01–1.3 5- SD 0.296) and hyposali-
vation was more intense in the Groups II/III(p5 0.007). There was
no correlation of taste dysfunction with oral cGVHD lesions. The
results indicate that, despite the hyposalivation, taste alterations
were only observed for the sweet and salty tastes even in patients
up to 3 years post-HSCT. These results may indicate that taste alter-
ations post-HSCT are not correlated to oral cGVHD and to hypo-
salivation but may be considered as an individual response of the
HSCT.142
RELATIVE IMPACT OF PSYCHOSOCIAL FACTORS, COMORBIDITIES, AND
DISEASE RISK ON THE UTILIZATION OF RESOURCES AND OVERALL
OUTCOME IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speckhart, D.S.1, Holland, H.K.1,2, Solomon, S.R.1,2, Bashey, A.1,2,
Morris, L.E.1,2, Kerns, L.1, Berry, T.1 1The Blood and Marrow Trans-
plant Program at Northside Hospital, Atlanta, GA; 2The Blood and
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Several studies have begun to examine the relationship between
psychosocial variables and outcome in hematopoietic stem cell trans-
plantation (HSCT). Previous studies have also looked at the rela-
tionship between the Hematopoietic Cell Transplantation
Comorbidity Index (HCT-CI) and overall survival in HSCT which
demonstrated a negative relationship between HCT-CI and overall
survival. In this study, data was collected on 128 patients undergoing
HSCT. Based on the patient’s TERS score, each patient was strati-
fied into one of two groups (low/moderate risk (n5 96) vs. high risk
(n 5 32)) based on their predicted psychosocial risk for problems
during transplant. Patients were also stratified into two categories
on the HCT-CI (low (n5 102) vs. high (n5 26)) based on the num-
ber of comorbid features present pre-transplant. Patients were also
grouped into disease risk categories as classified by the CIBMTR
criteria. Only the TERS was found to be a significant predictor of
utilization of resources (length of hospitalization) between low/mod-
erate risk (26 days) versus high risk (40 days) patients (p\.02). The
HCT-CI (p 5 .014) and CIBMTR disease risk status (p 5 .02)
were found to be significantly correlated with overall survival. Alone,
the TERS showed a similar trend but did not appear to have a signif-
icant impact on overall survival. Those patients who scored lowest on
all three measures (TERS, HCT-CI and CIBMTR disease risk) had
the best overall survival rate, nearing 75% survival at 2 years post
HSCT. One would conclude that although psychosocial factors im-
pact the utilization of resources, well equipped transplant centers can
provide a relatively safe method for high risk psychosocial patients to
undergo HSCT. These results reinforce the impact of the HCT-CIand disease risk on transplant outcome previously found at other
large transplant centers.143
SOLID ORGAN TRANSPLANTATION IN SURVIVORS OF HEMATOPOIETIC
CELL TRANSPLANTATION: A SINGLE INSTITUTION CASE SERIES
Beitinjaneh, A., Burns, L., Majhail, N. University of Minnesota,
Mineapolis, MN
Advancements in the field of hematopoietic cell transplantation
(HCT) has led to an increasing number of long-term HCT survi-
vors. For selected survivors with severe organ dysfunction, solid or-
gan transplantation (SOT) may offer the best chance for better
quality of life and extended survival. However, SOT following
HCT has not been well described. We report a single institution
experience of SOT in 11 HCT recipients. Transplanted organs
included kidney (N 5 7), lung (N 5 2), liver (N 5 2) and heart
(N 5 1). Age at HCT ranged from 2 to 59 years. All patients were
100% donor engrafted and in complete remission from their under-
lyingmalignancy at the time of SOT. Among recipients of allogeneic
HCT, 5/9 had a history of chronic graft-versus-host disease
(GVHD); only three patients had active GVHD at the time of
SOT. Median time between HCT and SOT was 7.4 years (range
1.2–15.9 years). Four patients have died, one patient received his
SOT at another institution and was lost for followup, while six
patients are alive with a median followup of 2 years (range 0.5 – 6
years). Among the 10 patients with post-SOT followup information,
9 had normal function of the transplanted solid organ at the time of
last contact or death. Two patients developed cytomegalovirus reac-
tivation, one patient developed post transplantation lymphoprolifer-
ative disorder, and one patient developed second malignancy after
SOT. SOT is feasible in selected HCT recipients with organ failure
and is associated with favorable long-term survival and graft func-
tion. More research is needed to further delineate the subset of
HCT survivors who will benefit the most with SOT with the least
risk of significant complications.
Patients’ characteristics and outcome
Patient Organ & Time b/w Follow-upage/sex HCT type Diagnosis Indication HCT & SOT after SOT27 F Autologous Hodgkin’s
lymphomaLung,
Interstitial
fibrosis7.4 yrs 2 yrs, alive56 M Autologous Myeloma Cadaveric
kidney,
ESRD2.9 yrs 2 yrs, alive37 M Allo Sib Aplastic
anemiaSibling
kidney,
ESRD5.6 yrs 8.9 yrs,
dead
(ischemic
cardiomyopathy)46 M Allo Sib Mantle
cell
lymphomaSibling
kidney,
ESRD7.4 yrs 2.2 yrs, dead
(metastatic
squamous
cell cancer
of tongue)59 M Allo Sib CML Sibling
kidney,
ESRD15.9 yrs 5.9 yrs, alive41 M Allo MUD CML Combined
heart and
cadaveric kidney,
Cardiomyopathy
and ESRD12.3 yrs 0.5 yrs, alive2 F Allo Sib Neurob
lastomaSibling kidney,
ESRD9.3 yrs 6 yrs, alive8 F Allo Sib AML Cadaveric liver,
HCV cirrhosis6.5 yrs 1 mo, dead
(aspergillosis)12 M Allo Sib Aplastic
anemiaCadaveric liver,
fulminant
hepatitis9.8 yrs 1.5 yrs, alive(Continued )
